Earnings call transcript: AngioDynamics beats Q1 2026 forecasts as shares fall premarket
AngioDynamics reported a narrower-than-expected Q1 2027 loss of $0.04 per share, beating estimates of $0.11. Revenue rose 6.9% to $80.9M, slightly above forecasts. Shares fell 2.96% premarket. Med Tech revenue grew 13.2%, now 49% of total sales. Full-year guidance remained unchanged, with revenue expected between $336M and $341M.
How this was made
The 30-second read
Why it matters
The earnings beat was narrow and guidance unchanged, leading to a pre‑market sell‑off as investors weigh cash burn versus margin improvement.
Market read
First‑time earnings release for AngioDynamics; modest impact on broader market but relevant for med‑tech investors.
What to watch
Tariff refunds boosted gross margin; continued reimbursement progress for NanoKnife could improve cash flow later in the year.
Background
AngioDynamics is transitioning from traditional medical devices to higher‑growth MedTech products.
Ticker impact
AngioDynamics reported Q1 2026 earnings beating loss expectations but shares fell 2.96% pre‑market.
modest downside as market prices in unchanged guidance and cash outflow concerns
The earnings beat was modest and revenue beat minimal; investors focused on full‑year outlook and cash burn, driving the pre‑market decline.
Market effects
MedTech segment shows stronger growth, may boost peer valuations in the medical device space.
U.S. small‑cap medical device stocks could see slight pressure as investors reassess cash usage.
Limited; impact confined to U.S. med‑tech equities.
Counterpoint
Despite the share drop, the earnings beat and margin expansion could support a short‑term bounce.
Key entities
- ExecutiveJim Clemmer
CEO who highlighted the 21st straight quarter of double‑digit growth.
- ExecutiveSteve Trowbridge
CFO who explained gross‑margin drivers and outlook.
